Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vibha Sharma

Vibha Sharma is a senior reporter covering pharmaceutical and medtech regulatory developments across the globe. She joined Scrip Regulatory Affairs in September 2010 and has since then been at the center of deciding and writing news on important regulatory issues affecting the pharma and medtech sectors and explaining their implications for the industry.

Her fields of interest include the EU Pharmacovigilance legislation and the EU Paediatrics Regulation on which she has written several exclusive articles from various industry conferences. She has also commissioned some pieces of expert analysis on major developments in the pharma and medtech regulatory arenas.

Before joining Informa, she was principal correspondent with India's national newspaper Hindustan Times, where she reported on health and medical issues, besides several other topics. She has also worked with two other Indian national dailies, The Indian Express and The Asian Age.

Advertisement
Set Alert for Articles By Vibha Sharma

Latest From Vibha Sharma

EU Initiative Flags Up Challenging Products For Regulators

A new EU group is keeping a bird's eye view on new innovative medicinal products being brought before member states’ innovation offices, and has flagged up "emerging challenges" and "interesting cases" identified throughout 2017 that need further discussion at the level of the EU medicines network.

Innovation Regulation

EMA To Establish Minimum Requirements For CAR-T Cell Registries

The European Medicines Agency is exploring the possibility of establishing minimum requirements for all CAR-T Cell registries in the EU to facilitate efficient data collection on such products in the post-authorization phase.

Post Market Regulation & Studies Regulation

Combined Effect Of EU Pediatrics And Orphan Drugs Legislation Under EU Commission Scrutiny

A joint evaluation of the EU pediatrics and orphan drugs legislation is due to commence next year in an effort to understand why the two legal instruments have failed to encourage companies to develop medicines targeting rare diseases in children. The initiative will help decide the possible need for future changes.

Pediatrics Rare Diseases

EU Guideline On Investigational ATMPs Delayed Until Q3 2019

Several factors have contributed towards a delay in the European Medicines Agency's much awaited guideline on investigational advanced therapy medicinal products, which was initially due to be finalized in the second quarter of 2017.

Clinical Trials Regulation

EU Sets Up Database Of National GMO Requirements To Facilitate ATMP Trials

The European Commission has developed a database to help drug companies navigate the complex process of seeking environmental clearance from EU member states before they can initiate a clinical trial with ATMPs containing a genetically modified organism.

Clinical Trials Regulation

EU Regulators Urge Pharma To Share Their Brexit Plans

Sponsors of medicines evaluated through the EU's decentralized procedure are being urged to share their plans regarding Brexit with national agencies as soon as possible to help with planning. The head of the Dutch Medicines Agency thinks that the human medicines sector can learn from the progress being made in the veterinary space on this front.

Brexit Regulation
See All
Advertisement
UsernamePublicRestriction

Register